Sevelamer and CKD-associated cardiovascular disease: going further, but far from there.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23989354.
- Also identified by DOI 10.1038/ki.2013.160.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cardiovascular disease is a major complication of chronic kidney disease (CKD), and current data support its link to mineral metabolism disturbances. However, there is an intense debate over whether CKD-mineral and bone disorder therapy could change the cardiovascular burden in CKD. The study by Maizel and colleagues shows the benefits of a phosphate binder, sevelamer, for the progression of aortic stiffness and endothelial dysfunction as well as left ventricular dysfunction and hypertrophy in mice with CKD.
Medical subject headings
- Cardiovascular System
- Hypertrophy, Left Ventricular
- Kidney Failure, Chronic
- Polyamines
- Vascular Stiffness